Cargando…

Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis

Although primary systemic amyloid light-chain amyloidosis was considered intractable, recent advances in therapy have been reported to result in better clinical outcomes including remission of nephrotic syndrome. However, changes in renal pathologic findings after high-dose chemo- therapy have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoshino, Junichi, Ubara, Yoshifumi, Ohashi, Kenichi, Takemoto, Fumi, Takaichi, Kenmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840819/
https://www.ncbi.nlm.nih.gov/pubmed/24282444
http://dx.doi.org/10.1093/ndtplus/sfn144
_version_ 1782478564805836800
author Hoshino, Junichi
Ubara, Yoshifumi
Ohashi, Kenichi
Takemoto, Fumi
Takaichi, Kenmei
author_facet Hoshino, Junichi
Ubara, Yoshifumi
Ohashi, Kenichi
Takemoto, Fumi
Takaichi, Kenmei
author_sort Hoshino, Junichi
collection PubMed
description Although primary systemic amyloid light-chain amyloidosis was considered intractable, recent advances in therapy have been reported to result in better clinical outcomes including remission of nephrotic syndrome. However, changes in renal pathologic findings after high-dose chemo- therapy have not been characterized. We describe a patient who underwent serial renal biopsies and had complete remission after high-dose melphalan and autologous stem cell transplantation for this form of amyloidosis. Successive renal biopsy specimens showed reduction in amyloid staining mainly in interlobular arterial and arteriolar walls. Thus, amyloid light-chain amyloidosis resolved both clinically and pathologically after high-dose chemotherapy.
format Online
Article
Text
id pubmed-3840819
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-38408192013-11-26 Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis Hoshino, Junichi Ubara, Yoshifumi Ohashi, Kenichi Takemoto, Fumi Takaichi, Kenmei NDT Plus Case Reports Although primary systemic amyloid light-chain amyloidosis was considered intractable, recent advances in therapy have been reported to result in better clinical outcomes including remission of nephrotic syndrome. However, changes in renal pathologic findings after high-dose chemo- therapy have not been characterized. We describe a patient who underwent serial renal biopsies and had complete remission after high-dose melphalan and autologous stem cell transplantation for this form of amyloidosis. Successive renal biopsy specimens showed reduction in amyloid staining mainly in interlobular arterial and arteriolar walls. Thus, amyloid light-chain amyloidosis resolved both clinically and pathologically after high-dose chemotherapy. Oxford University Press 2008-12 2008-09-01 /pmc/articles/PMC3840819/ /pubmed/24282444 http://dx.doi.org/10.1093/ndtplus/sfn144 Text en © The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Reports
Hoshino, Junichi
Ubara, Yoshifumi
Ohashi, Kenichi
Takemoto, Fumi
Takaichi, Kenmei
Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
title Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
title_full Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
title_fullStr Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
title_full_unstemmed Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
title_short Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
title_sort pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840819/
https://www.ncbi.nlm.nih.gov/pubmed/24282444
http://dx.doi.org/10.1093/ndtplus/sfn144
work_keys_str_mv AT hoshinojunichi pathologicimprovementafterhighdosemelphalanandautologousstemcelltransplantationforprimarysystemicamyloidosis
AT ubarayoshifumi pathologicimprovementafterhighdosemelphalanandautologousstemcelltransplantationforprimarysystemicamyloidosis
AT ohashikenichi pathologicimprovementafterhighdosemelphalanandautologousstemcelltransplantationforprimarysystemicamyloidosis
AT takemotofumi pathologicimprovementafterhighdosemelphalanandautologousstemcelltransplantationforprimarysystemicamyloidosis
AT takaichikenmei pathologicimprovementafterhighdosemelphalanandautologousstemcelltransplantationforprimarysystemicamyloidosis